REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Peptide Library

AHK-Cu

Ala-His-Lys-Cu / Copper Peptide AHK

Recovery & Repair

AHK-Cu (Copper Tripeptide Ala-His-Lys-Cu) is a copper-binding tripeptide variant consisting of alanine-histidine-lysine complexed with a copper(II) ion, studied for its potential role in hair growth stimulation and skin rejuvenation. It is structurally related to the more extensively studied GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) but with alanine substituted for glycine at the first position, potentially altering its receptor interactions and biological activity profile. Research applications focus primarily on dermal papilla cell stimulation, wound healing, and cosmetic anti-aging formulations.

Mechanism of Action

Synthetic copper-binding tripeptide analog of GHK-Cu with alanine substituted for glycine. Stimulates collagen synthesis and dermal fibroblast proliferation. May offer enhanced stability over GHK-Cu while maintaining copper-dependent tissue remodeling activity.

Research Protocols

For research purposes only. Not medical advice.

Research protocols mirror GHK-Cu. Topical: 1-2% concentration. Injectable protocols not well-established. Primarily studied in cosmetic formulations.

Research Notes

Clinical Research Status

AHK-Cu has significantly less published clinical research compared to its well-studied relative GHK-Cu, with most available data coming from in vitro cell culture studies and cosmetic ingredient characterization rather than formal clinical trials. Patent literature and cosmetic industry research reports suggest efficacy in hair follicle stimulation, but independent peer-reviewed clinical validation remains limited. It is available as a cosmetic ingredient and in topical hair growth formulations, but has not been evaluated by the FDA for any medical indication.

Key Published Findings

In vitro studies on human dermal papilla cells demonstrate that AHK-Cu stimulates proliferation and increases production of vascular endothelial growth factor (VEGF) and other growth factors associated with hair follicle angiogenesis. Comparative studies suggest AHK-Cu may have superior hair growth stimulation activity compared to GHK-Cu in certain cell culture models, possibly due to different binding dynamics at the cellular level. The copper ion is essential for activity, participating in extracellular matrix remodeling through lysyl oxidase activation and superoxide dismutase function.

Safety Profile

Copper peptides generally have an excellent topical safety profile, with AHK-Cu showing no significant irritation or sensitization in available patch testing data. Systemic copper toxicity is not a concern at concentrations used in topical formulations (typically 0.001-0.1%). As with all copper peptides, high concentrations may produce a blue-green discoloration of skin or products, and interactions with ascorbic acid (vitamin C) can cause oxidative degradation of both compounds when co-formulated.

Comparison to Related Compounds

GHK-Cu is the most extensively studied copper peptide with over 100 published papers documenting wound healing, anti-inflammatory, and anti-aging effects, while AHK-Cu has a much smaller research base. The alanine substitution in AHK-Cu may provide different tissue specificity or potency for hair follicle applications compared to GHK-Cu's broader tissue effects. Both copper peptides differ fundamentally from minoxidil (a potassium channel opener) and finasteride (a 5-alpha reductase inhibitor), working through growth factor and extracellular matrix pathways rather than vascular or hormonal mechanisms.

Community Observations

Hair loss communities have shown growing interest in AHK-Cu as an addition to topical hair growth regimens, often combined with GHK-Cu, minoxidil, and microneedling protocols. Users report that results are gradual and modest, typically requiring 3-6 months of consistent application to assess efficacy. The peptide is available from specialized cosmetic ingredient suppliers and is increasingly appearing in commercial hair growth serums, though concentration standardization varies significantly between products.

Half-Life

~30-60 minutes

Reconstitution

Bacteriostatic water (BAC)

Storage

Lyophilized

Refrigerate 2-8C up to 12 months.

Reconstituted

Refrigerate 2-8C. Use within 14 days.

US Legal Status

Cosmetic/research ingredient

Also Known As

Ala-His-Lys-CuCopper Peptide AHK

PeptideVault provides research-based summaries for informational purposes only. We do not host, distribute, or endorse vendor documentation. All certificates of analysis, GMP certificates, and vendor communications must be requested and verified directly by the buyer. Nothing on this platform constitutes legal, medical, or professional advice. Users are solely responsible for verifying vendor credentials and ensuring compliance with all applicable local, state, and federal laws before purchasing any research chemicals. Use of this platform constitutes acceptance of full personal responsibility.

Read full disclaimer